Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobolimab - AnaptysBio/GSK

Next Previous
Drug Profile

Cobolimab - AnaptysBio/GSK

Alternative Names: Anti-TIM-3-antibody-GSK; GSK-4069889; TSR 022; WBP 296A

Latest Information Update: 27 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnaptysBio
  • Developer AnaptysBio; GSK; TESARO; University of Pittsburgh
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Cervical cancer; Liver cancer; Malignant melanoma
  • Phase I/II Solid tumours

Most Recent Events

  • 31 Dec 2024 AnaptysBio has patent protection for antibody sequence of Cobolimab and its variants, methods of use and related matters in multiple countries
  • 31 Dec 2024 AnaptysBio has patents pending for Cobolimab in multiple countries
  • 20 Dec 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, In neonates, In infants, In children, In adolescents, In adults) in USA (Parenteral) (NCT06521567)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top